文献速递妇科

新辅助化疗后行间歇性肿瘤细胞减灭术对晚期非浆液性卵巢癌、输卵管癌或原发性腹膜癌患者生存的影响

Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.
PubMed 文献 · Gynecol Oncol · 2025-10-22

基于日本妇产科学会肿瘤登记库(2017至2022年)的回顾性分析纳入20212例FIGO III-IV期卵巢、输卵管或原发性腹膜癌患者,比较新辅助化疗后间歇性肿瘤细胞减灭术(NACT/IDS)与初次肿瘤细胞减灭术(PDS)的生存影响。非高级别浆液性癌(非HGSC)独立关联更差的总生存(校正HR 1.35,P<.001),其升级/IDS失败率36%高于HGSC的25%(P<.001);倾向评分匹配后,NACT后实现IDS的HGSC患者5年OS与PDS相当(36.8% vs 35.6%;HR 0.83,P=.12),而IDS失败者生存显著更差(3.9%;HR 3.12,P<.001)。

要点

  • 非HGSC组织学独立关联更差OS(校正HR 1.35,P<.001)。
  • 非HGSC升级/IDS失败率36%,高于HGSC的25%(P<.001)。
  • 匹配后NACT后实现IDS者5年OS与PDS相当(36.8% vs 35.6%;HR 0.83,P=.12)。

核心结论

  • 非HGSC患者NACT后升级/IDS失败率约36%,但NACT后实现IDS者生存与PDS相当,强调需选择合适候选者。

研究设计与样本

  • 基于日本妇产科学会肿瘤登记库(2017至2022年)的回顾性分析,纳入FIGO III-IV期卵巢、输卵管或原发性腹膜癌患者20212例,按组织学分为HGSC与非HGSC并比较初始治疗。

主要发现

  • 20212例中HGSC 14718例(72.8%),非HGSC 5494例(27.2%),主要为透明细胞癌2389例(11.8%)和子宫内膜样癌1431例(7.1%)。
  • HGSC中7118例(48.4%)接受NACT,非HGSC中1203例(21.9%)接受NACT。
  • 与HGSC相比,非HGSC患者更年轻、更多登记于日本东部、更多诊断于FIGO 2014 IIIA/IIIB期、更多接受PDS和淋巴结评估(均P<.05)。
  • 전체 코호트에서 비HGSC 조직학은 독립적으로 더 나쁜 OS와 연관됨(보정 HR 1.35,P<.001)。
  • 倾向评分匹配后,HGSC中NACT后实现IDS者与PDS者5年OS相当(36.8% vs 35.6%;HR 0.83,P=.12),而IDS失败与生存显著更差相关(3.9%;HR 3.12,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the survival impact of neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) versus primary debulking surgery (PDS) in patients with advanced epithelial ovarian cancer of non-high-grade serous carcinoma (HGSC) histology. METHODS: A retrospective analysis was conducted using the Japan Society of Obstetrics and Gynecology tumor registry (2017 to 2022). Patients with FIGO stage III-IV ovarian, fallopian tube, or primary peritoneal cancer were classified by histology (HGSC or non-HGSC), and compared initial treatment. Overall survival (OS) was analyzed using multivariate Cox proportional hazard model and propensity score matching (PSM). RESULTS: Among 20,212 eligible cases, 14,718 (72.8 %) were HGSC and 5494 (27.2 %) were non-HGSC, primarily clear cell (2389;11.8 %) and endometrioid (1431;7.1 %) carcinomas. In HGSC patients, 7118 (48.4 %) received NACT, while in non-HGSC, 1203 (21.9 %) received NACT. Compared with HGSC, non-HGSC patients were younger, more frequently registered in eastern Japan, diagnosed at FIGO 2014 stage IIIA/IIIB, and underwent PDS and nodal evaluation (all, P < .05). In the overall cohort, non-HGSC histology was independently associated with poorer OS (adjusted-hazard ratio [HR]1.35, P < .001). Upstaging/IDS failure was higher in non-HGSC (36 %) vs HGSC (25 %, P < .001). After PSM, 5-year OS was comparable between HGSC patients who achieved IDS after NACT and those who underwent PDS (36.8 % vs 35.6 %; HR0.83, P = .12), whereas IDS failure was associated with markedly worse survival (3.9 %; HR3.12, P < .001). CONCLUSION: In non-HGSC, the rate of upstaging/IDS failure after NACT reached approximately 36 %; however, achieving IDS after NACT resulted in survival comparable to PDS, highlighting the need to select appropriate candidates.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Machida H, Kawana K, Okamoto A, et al. Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2025. PMID: 41129878. doi:10.1016/j.ygyno.2025.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。